Dividend Information About Gilead Sciences: Everything You Need to Know Before Its Ex-Dividend Date on Sep 15, 2025
Generado por agente de IAAinvest Dividend Digest
jueves, 11 de septiembre de 2025, 7:05 pm ET1 min de lectura
GILD--
Gilead Sciences (GILD) recently announced a cash dividend of $0.79 per share, with an ex-dividend date set for Sep 15, 2025, and a payment date of Sep 29, 2025. The announcement was made on Jul 29, 2025, marking the second consecutive dividend at the same amount of $0.79 per share, as the last dividend was also issued on Jun 27, 2025. This upcoming payout is higher than the average of the last 10 dividend amounts, which stood at approximately $0.6378 per share, indicating a positive trend in the company’s dividend policy. Investors should be aware that Sep 15, 2025, is the last day to purchase the stock and still receive this dividend; any purchase made after this date will not qualify for the current payout.
Over the past week, Gilead SciencesGILD-- has been in the spotlight due to several key developments that highlight its ongoing strategic and operational momentum. Analysts recently raised their target price for GILDGILD-- to $130, signaling renewed confidence in the company’s long-term growth potential. This follows recent positive momentum in its pipeline, particularly in HIV prevention and treatment, which continues to be a core focus for the company. Additionally, institutional investors have been increasing their stakes in the stock, with Woodline Partners LP growing its holdings by 2.2% in the first quarter of 2025, suggesting strong backing from key players in the market.
As of late, GileadGILD-- has also seen positive short-term price movements, with its shares up 0.7% in recent trading. The stock closed at $115.25 on the last market day, showing a modest rebound despite a recent decline of $0.51 in its price. Investors appear to be reacting positively to the company’s continued innovation in virology and oncology, particularly with its marketed products such as Biktarvy and Genvoya. With a strong balance sheet and a diverse portfolio of therapies addressing critical unmet medical needs, Gilead remains well-positioned to navigate the evolving biopharma landscape.
Given the recent developments, including the upcoming dividend and the upward revision in analyst price targets, Gilead Sciences continues to attract attention from both long-term and short-term investors. With its ex-dividend date approaching on Sep 15, 2025, shareholders and potential investors should be mindful of the cutoff for dividend eligibility. As the company advances its pipeline and strengthens its market presence, the next few weeks will be crucial for assessing its performance and its ability to sustain investor interest.
Over the past week, Gilead SciencesGILD-- has been in the spotlight due to several key developments that highlight its ongoing strategic and operational momentum. Analysts recently raised their target price for GILDGILD-- to $130, signaling renewed confidence in the company’s long-term growth potential. This follows recent positive momentum in its pipeline, particularly in HIV prevention and treatment, which continues to be a core focus for the company. Additionally, institutional investors have been increasing their stakes in the stock, with Woodline Partners LP growing its holdings by 2.2% in the first quarter of 2025, suggesting strong backing from key players in the market.
As of late, GileadGILD-- has also seen positive short-term price movements, with its shares up 0.7% in recent trading. The stock closed at $115.25 on the last market day, showing a modest rebound despite a recent decline of $0.51 in its price. Investors appear to be reacting positively to the company’s continued innovation in virology and oncology, particularly with its marketed products such as Biktarvy and Genvoya. With a strong balance sheet and a diverse portfolio of therapies addressing critical unmet medical needs, Gilead remains well-positioned to navigate the evolving biopharma landscape.
Given the recent developments, including the upcoming dividend and the upward revision in analyst price targets, Gilead Sciences continues to attract attention from both long-term and short-term investors. With its ex-dividend date approaching on Sep 15, 2025, shareholders and potential investors should be mindful of the cutoff for dividend eligibility. As the company advances its pipeline and strengthens its market presence, the next few weeks will be crucial for assessing its performance and its ability to sustain investor interest.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios